Overview
Compare with PRO DEX INC, TELA Bio, Inc. or Avita Medical, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
86.2%Gross margin3
-48.0%Operating margin3
-49.7%Net margin3
-3.1%Revenue growth, 20253
-60.1%Return on equity3
0.63×Debt to equity3
-$29.9MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Surgical Glaucoma brought in 98% of the revenue Sight Sciences, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Surgical Glaucoma | $75.9M | $75.7M |
| Dry Eye | $4.0M | $1.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue9¢$10.7M
- Research and development12¢$14.6M
- Selling, general and admin75¢$89.2M
- Interest4¢$5.1M
- Income tax0¢$10.0K
Out of $77.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $77.4M | $79.9M |
| Cost of goods sold | $10.7M | $11.6M |
| Gross profit | $66.7M | $68.3M |
| Research and development | $14.6M | $18.0M |
| Selling, general and administrative | $89.2M | $100.8M |
| Total operating expenses | $103.8M | $118.8M |
| Loss from operations | -$37.1M | -$50.5M |
| Investment income | $4.0M | $5.9M |
| Interest expense | -$5.1M | -$4.7M |
| Loss on debt extinguishment | $0 | -$2.0M |
| Other expense, net | -$148.0K | -$32.0K |
| Loss before income taxes | -$38.4M | -$51.3M |
| Provision for income taxes | $10.0K | $236.0K |
| Net loss and comprehensive loss | -$38.4M | -$51.5M |
| Net loss per share attributable to common stockholders-basic | -$0.74 | -$1.03 |
| Net loss per share attributable to common stockholders-diluted | -$0.74 | -$1.03 |
| Weighted-average shares of common stock outstanding-basic | 52.1M shares | 50.1M shares |
| Weighted-average shares of common stock outstanding-diluted | 52.1M shares | 50.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $92.0M | $120.4M | |
| Accounts receivable, net of allowance for credit losses of $234 and $689 at December 31, 2025 and 2024, respectively | $9.7M | $10.8M | |
| Inventory, net | $7.8M | $6.3M | |
| Prepaid expenses and other current assets | $3.3M | $2.3M | |
| Total current assets | $112.7M | $139.8M | |
| Property and equipment, net | $1.6M | $1.6M | |
| Operating lease right-of-use assets | $438.0K | $935.0K | |
| Other noncurrent assets | $518.0K | $550.0K | |
| Total assets | $115.3M | $142.8M | |
| Accounts payable | $1.3M | $1.7M | |
| Accrued compensation | $6.1M | $9.7M | |
| Accrued and other current liabilities | $3.6M | $4.1M | |
| Total current liabilities | $11.0M | $15.5M | |
| Long-term debt, net of current portion | $40.3M | $39.4M | |
| Other noncurrent liabilities | $31.0K | $492.0K | |
| Total liabilities | $51.4M | $55.3M | |
| Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | |
| Common stock, par value $0.001 per share; 200,000,000 shares authorized; 53,493,711 and 50,937,999 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $54.0K | $51.0K | |
| Additional paid-in-capital | $448.6M | $433.8M | |
| Accumulated deficit | -$384.7M | -$346.3M | |
| Total stockholders' equity | $63.9M | $87.5M | $120.2M |
| Total liabilities and stockholders' equity | $115.3M | $142.8M | |
| Accounts Receivable, net of Allowance for Credit Losses | $234.0K | $689.0K | |
| Preferred stock par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred Stock, Shares Issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common Stock Shares Issued | 53.5M shares | 50.9M shares | |
| Common Stock Shares Outstanding | 53.5M shares | 50.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $92.0M | $120.4M | |
| Accounts receivable, net of allowance for credit losses of $234 and $689 at December 31, 2025 and 2024, respectively | $9.7M | $10.8M | |
| Inventory, net | $7.8M | $6.3M | |
| Prepaid expenses and other current assets | $3.3M | $2.3M | |
| Total current assets | $112.7M | $139.8M | |
| Property and equipment, net | $1.6M | $1.6M | |
| Operating lease right-of-use assets | $438.0K | $935.0K | |
| Other noncurrent assets | $518.0K | $550.0K | |
| Total assets | $115.3M | $142.8M | |
| Accounts payable | $1.3M | $1.7M | |
| Accrued compensation | $6.1M | $9.7M | |
| Accrued and other current liabilities | $3.6M | $4.1M | |
| Total current liabilities | $11.0M | $15.5M | |
| Long-term debt, net of current portion | $40.3M | $39.4M | |
| Other noncurrent liabilities | $31.0K | $492.0K | |
| Total liabilities | $51.4M | $55.3M | |
| Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | |
| Common stock, par value $0.001 per share; 200,000,000 shares authorized; 53,493,711 and 50,937,999 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $54.0K | $51.0K | |
| Additional paid-in-capital | $448.6M | $433.8M | |
| Accumulated deficit | -$384.7M | -$346.3M | |
| Total stockholders' equity | $63.9M | $87.5M | $120.2M |
| Total liabilities and stockholders' equity | $115.3M | $142.8M | |
| Accounts Receivable, net of Allowance for Credit Losses | $234.0K | $689.0K | |
| Preferred stock par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred Stock, Shares Issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common Stock Shares Issued | 53.5M shares | 50.9M shares | |
| Common Stock Shares Outstanding | 53.5M shares | 50.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$38.4M | -$51.5M |
| Depreciation and amortization | $487.0K | $712.0K |
| Accretion of debt discount and debt issuance costs | $944.0K | $753.0K |
| Stock-based compensation expense | $13.1M | $17.1M |
| Allowance for credit losses | $129.0K | -$42.0K |
| Provision (benefit) for excess and obsolete inventories | $0 | -$106.0K |
| Noncash operating lease cost | $498.0K | $646.0K |
| Loss on disposal of property and equipment | $4.0K | $23.0K |
| Noncash loss on debt extinguishment | $0 | $1.0M |
| Change in fair value of common stock warrants | $11.0K | $60.0K |
| Accounts receivable | $912.0K | $3.5M |
| Inventory | -$1.4M | $1.6M |
| Prepaid expenses and other current assets | -$686.0K | $299.0K |
| Other noncurrent assets | -$150.0K | -$51.0K |
| Accounts payable | -$348.0K | $336.0K |
| Accrued compensation | -$3.6M | $5.2M |
| Accrued and other current liabilities | -$1.1M | -$347.0K |
| Other noncurrent liabilities | $0 | -$1.6M |
| Net cash used in operating activities | -$29.7M | -$22.4M |
| Purchases of property and equipment | -$224.0K | -$385.0K |
| Net cash used in investing activities | -$224.0K | -$385.0K |
| Net proceeds from Hercules Loan Agreement | $0 | $39.5M |
| Repayment of MidCap Loan Agreement | $0 | -$35.4M |
| Debt issuance costs | $0 | -$238.0K |
| Proceeds from exercise of common stock options | $1.1M | $255.0K |
| Taxes paid on net settlement of restricted stock units | -$58.0K | -$23.0K |
| Proceeds from employee stock purchase plan purchases | $758.0K | $819.0K |
| Net cash provided by financing activities | $1.8M | $5.0M |
| Net change in cash and cash equivalents | -$28.1M | -$17.8M |
| Cash paid for interest | $4.2M | $4.3M |
| Acquisition of property and equipment included in accounts payable and accrued liabilities | $114.0K | $169.0K |
| Common stock warrants issued upon execution of Hercules Loan Agreement | $0 | $687.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Sight Sciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Sight Sciences, Inc.
- KCK LTD. Filed SCHEDULE 13G/A on Sight Sciences, Inc., latest Apr 8, 2026 (5 filings since Feb 13, 2023)
- BlackRock Filed SCHEDULE 13G on Sight Sciences, Inc., latest Jan 21, 2026
- Long Focus Capital Management, LLC Filed SCHEDULE 13G/A on Sight Sciences, Inc., latest May 15, 2025 (2 filings since Jan 23, 2025)
- Staffan Encrantz Filed SCHEDULE 13D/A on Sight Sciences, Inc., latest Mar 13, 2025 (4 filings since Dec 10, 2021)
- Bank of America Filed SC 13G/A on Sight Sciences, Inc., latest Nov 14, 2024 (2 filings since Feb 13, 2024)
- UBS Filed SCHEDULE 13G/A on Sight Sciences, Inc., latest Aug 8, 2024 (2 filings since Feb 7, 2024)
- D1 Capital Partners L.P. Filed SC 13G/A on Sight Sciences, Inc., latest Jan 10, 2024
- HEP Partners LLC Filed SC 13G/A on Sight Sciences, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Paul Badawi Filed SC 13G/A on Sight Sciences, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- SHD GP II, LLC Filed SC 13D/A on Sight Sciences, Inc., latest Apr 18, 2022
- Jesse Selnick Filed SC 13G on Sight Sciences, Inc., latest Feb 14, 2022
- Sight Sciences, Inc. Menlo Park, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Sight Sciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $4.0M3 Dec 31, 2025 | $3.7M3 Dec 31, 2024 | +8.8% |
| Accumulated depreciation | $2.4M3 Dec 31, 2025 | $2.1M3 Dec 31, 2024 | +14.0% |
| Property and equipment, net | $1.6M3 Dec 31, 2025 | $1.6M3 Dec 31, 2024 | +1.9% |
| Operating-lease assets (leased space) | $438.0K3 Dec 31, 2025 | $935.0K3 Dec 31, 2024 | −53.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $92.0M3 Dec 31, 2025 | $120.4M3 Dec 31, 2024 | −23.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $7.8M3 Dec 31, 2025 | $6.3M3 Dec 31, 2024 | +22.8% |
| Raw materials | $1.2M3 Dec 31, 2025 | $1.0M3 Dec 31, 2024 | +20.0% |
| Finished goods | $6.8M3 Dec 31, 2025 | $5.6M3 Dec 31, 2024 | +21.4% |
Properties, in its own words
Our corporate headquarters are in Menlo Park, California, where we lease approximately 11,000 square feet of office, research and development, engineering and laboratory space pursuant to a lease that commenced on August 1, 2021. On January 29, 2026, the Company amended this lease to extend the term from October 31, 2026 to December 31, 2028. We also lease approximately 2,000 square feet of office space, which is primarily used by our commercial team, in Southlake, Texas, pursuant to a lease that commenced on April 30, 2019 and expires on May 15, 2026. We believe that our existing
facilities are adequate to meet our business requirements in the near-term, and that additional space will be available on commercially reasonable terms, if required.
Item 2 of the 10-K filed Mar 4, 2026.10
Leadership
Who has led Sight Sciences, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerPaul Badawi Jul 14, 2021 to now11
- PresidentPaul Badawi Jul 14, 2021 to now11
- Chief financial officerJames Rodberg Nov 6, 2025 to now12
- Chief financial officerAlison Bauerlein Feb 16, 2024 to Nov 6, 202513
- Chief financial officerJesse Selnick Jul 14, 2021 to Jan 5, 202314
- Chief operating officerAlison Bauerlein Nov 13, 2025 to now15
Board members and other officers (20)
- EVP, OperationsBrenton Taylor Nov 5, 2024 to now16
- EVP, Research & DevelopmentManohar K. Raheja Nov 5, 2024 to now17
- OfficerJames Rodberg Jan 18, 2023 to Mar 21, 202318
- OfficerAlison Bauerlein Apr 5, 2023 to May 11, 202319
- Chief Commercial OfficerMatthew Link Sep 12, 2023 to now20
- Chief Technology OfficerDavid Badawi Jul 14, 2021 to now21
- Chief Commercial OfficerShawn O'Neil Jul 14, 2021 to Feb 11, 202222
- Board memberGerhard F. Burbach Apr 23, 2025 to now23
- Board memberBrenda Jane Larsen-Becker Mar 18, 2022 to now24
- Board memberTamara Fountain Jul 26, 2022 to now25
- Board memberAndrew Offer Jul 14, 2021 to Jul 19, 202126
- Board memberDavid Badawi Jul 14, 2021 to now21
- Board memberDonald Zurbay Jul 14, 2021 to now27
- Board memberErica J. Rogers Jul 14, 2021 to now28
- Board memberMack H. Hicks Jul 14, 2021 to Aug 5, 202229
- Board memberPaul Badawi Jul 14, 2021 to now11
- Board memberStaffan Encrantz Jul 14, 2021 to now30
- Board memberValeska Schroeder Jul 14, 2021 to Jun 12, 202331
- General counselKashif Rashid Aug 18, 2026 to now32
- General counselJeremy B. Hayden Jul 14, 2021 to now33
Timeline
- Aug 10, 20268-K Executive or director change34
- Aug 5, 20268-K Results of operations; Regulation FD disclosure35
- Jun 5, 20268-K Shareholder vote36
- May 6, 20268-K Results of operations; Regulation FD disclosure37
- Apr 23, 20268-K Regulation FD disclosure38
- Mar 30, 20268-K Regulation FD disclosure39
- Mar 4, 20268-K Results of operations; Regulation FD disclosure40
- Feb 3, 20268-K Entered a material agreement41
- Jan 13, 20268-K Results of operations42
- Nov 6, 20258-K Results of operations; Executive or director change; Regulation FD disclosure43
- Oct 17, 20258-K Regulation FD disclosure; Other events44
- Sep 30, 20258-K Entered a material agreement45
- Jul 14, 2021New chief executive Paul Badawi becomes CEO11
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.16) a share, on Nov 6, 2025.46
When it reported results
- Aug 5, 2026Reported quarterly or annual results35
- May 6, 2026Reported quarterly or annual results37
- Mar 4, 2026Reported quarterly or annual results40
- Jan 13, 2026Reported quarterly or annual results42
- Nov 6, 2025Reported quarterly or annual results43
- Aug 7, 2025Reported quarterly or annual results47
- May 8, 2025Reported quarterly or annual results48
- Mar 5, 2025Reported quarterly or annual results49
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
452 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 63 major events, 204 insider forms, 23 large holders, 142 other. The latest 20:
- Oct 5, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 2, 2026144 EDGAR
- Oct 2, 2026144 EDGAR
- Oct 2, 2026144 EDGAR
- Oct 1, 2026144 EDGAR
- Oct 1, 2026144 EDGAR
- Oct 1, 2026144 EDGAR
- Sep 30, 2026144 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 1, 2026144 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20263 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 2026144 EDGAR
- Aug 13, 2026144 EDGAR
- Aug 12, 2026144 EDGAR
The 452 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
122 open-market trades by officers, directors and large owners since October 2021: 38 buys and 84 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | HAYDEN JEREMY B.Chief Legal Officer | Sale | 12,733 | $5.51 | $70.2K | Form 4 |
| Jul 6, 2026 | Badawi DavidChief Technology Officer | Sale | 7,418 | $5.51 | $40.9K | Form 4 |
| Jul 2, 2026 | Rodberg JamesChief Financial Officer | Sale | 6,902 | $5.36 | $37.0K | Form 4 |
| Jul 2, 2026 | Bauerlein AlisonChief Operating Officer | Sale | 24,184 | $5.36 | $129.6K | Form 4 |
| Jul 1, 2026 | Taylor BrentonEVP, Operations & R&D | Sale | 2,829 | $5.42 | $15.3K | Form 4 |
| Jul 1, 2026 | Badawi PaulPresident and CEO | Sale | 28,684 | $5.42 | $155.5K | Form 4 |
| Jun 10, 2026 | Encrantz StaffanDirector | Buy | 14,100 | $4.88 | $68.8K | Form 4 |
| May 18, 2026 | Bauerlein AlisonChief Operating Officer | Sale | 12,728 | $5.12 | $65.2K | Form 4 |
| Apr 6, 2026 | Rodberg JamesChief Financial Officer | Sale | 7,231 | $3.55 | $25.7K | Form 4 |
| Apr 6, 2026 | HAYDEN JEREMY B.Chief Legal Officer | Sale | 13,761 | $3.55 | $48.9K | Form 4 |
| Apr 2, 2026 | Bauerlein AlisonChief Operating Officer | Sale | 25,874 | $3.48 | $90.0K | Form 4 |
| Apr 2, 2026 | Badawi DavidChief Technology Officer | Sale | 8,168 | $3.48 | $28.4K | Form 4 |
| Apr 1, 2026 | Taylor BrentonEVP, Operations & R&D | Sale | 2,869 | $3.70 | $10.6K | Form 4 |
| Apr 1, 2026 | Badawi PaulPresident and CEO | Sale | 29,244 | $3.70 | $108.2K | Form 4 |
| Jan 16, 2026 | Badawi DavidChief Technology Officer | Sale | 4,836 | $6.62 | $32.0K | Form 4 |
| Jan 16, 2026 | Rodberg JamesChief Financial Officer | Sale | 2,616 | $6.62 | $17.3K | Form 4 |
| Jan 16, 2026 | Badawi PaulPresident and CEO | Sale | 22,362 | $6.62 | $148.0K | Form 4 |
| Jan 16, 2026 | HAYDEN JEREMY B.Chief Legal Officer | Sale | 6,308 | $6.62 | $41.8K | Form 4 |
| Jan 6, 2026 | Badawi PaulPresident and CEO | Sale | 11,870 | $7.48 | $88.8K | Form 4 |
| Jan 6, 2026 | HAYDEN JEREMY B.Chief Legal Officer | Sale | 1,785 | $7.48 | $13.4K | Form 4 |
All 122 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- KCK LTD.SCHEDULE 13G/A, 5 filings Feb 13, 2023 to Apr 8, 202650
- BlackRockSCHEDULE 13G, 1 filing Jan 21, 202651
- Long Focus Capital Management, LLCSCHEDULE 13G/A, 2 filings Jan 23, 2025 to May 15, 202552
- Staffan EncrantzSCHEDULE 13D/A, 4 filings Dec 10, 2021 to Mar 13, 202553
- Bank of AmericaSC 13G/A, 2 filings Feb 13, 2024 to Nov 14, 202454
- UBSSCHEDULE 13G/A, 2 filings Feb 7, 2024 to Aug 8, 202455
- D1 Capital Partners L.P.SC 13G/A, 1 filing Jan 10, 202456
- HEP Partners LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202357
- Paul BadawiSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202358
- SHD GP II, LLCSC 13D/A, 1 filing Apr 18, 202259
- Jesse SelnickSC 13G, 1 filing Feb 14, 202260
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Paul BadawiPresident and Chief Executive Officer | 51 | $659.0K | $2.0M61 |
| 2025 | Alison BauerleinChief Operating Officer | 44 | $474.9K | $1.6M61 |
| 2025 | Matthew LinkChief Commercial Officer | $288.1K | $1.2M61 | |
| 2025 | Jeremy HaydenChief Legal Officer | 56 | $433.0K | $974.3K61 |
| 2024 | Paul BadawiPresident and Chief Executive Officer | 51 | $640.0K | $3.0M61 |
| 2024 | Alison BauerleinChief Operating Officer | 44 | $450.0K | $2.2M61 |
| 2024 | Jeremy HaydenChief Legal Officer | 56 | $420.0K | $1.5M61 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Sight Sciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSight Sciences, Inc.1
- CIK0001531177
- Employer ID (EIN)80-062574910
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company10
- Incorporated inDelaware10
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address4040 Campbell Ave,, Suite 100, Menlo Park, CA 940251
- Phone(415) 889-05501
- Shares outstanding55,087,990 as of Jul 31, 20269
- Public float$153.6M as of Jun 30, 202510
- AuditorDELOITTE & TOUCHE LLP, San Jose, California PCAOB ID 34; no auditor attestation of internal control over financial reporting10
- On EDGAR sinceSep 28, 20111
- Filings505 in all: 4 (198), 144 (122), 8-K (66), 3 (25), 10-Q (16), SC 13G (7), D (6), 10-K (5)1
All 33 form types
CORRESP (5), DEF 14A (5), DEFA14A (5), SC 13G/A (5), SCHEDULE 13G/A (5), SD (4), D/A (3), SC 13D/A (3), UPLOAD (3), 4/A (2), EFFECT (2), S-1/A (2), S-8 (2), SC 13D (2), SCHEDULE 13G (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), S-1 (1), S-3 (1), S-3/A (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 4, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 22, 2026
Latest 8-K (8-K) Aug 10, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 | SGHT | The Nasdaq Global Select Market |
From the cover page of the 10-K filed Mar 4, 2026 (Section 12(b) of the Exchange Act).10
Risk factors and legal proceedings
The risks Sight Sciences, Inc. names in Item 1A of its 10-K filed Mar 4, 2026: 52 risks under these headings, as written.10
- Risks Related to Our Business
- We are an early-stage company with a history of significant losses, we expect to incur losses in the future, and we may not be able to achieve or sustain profitability, which may make it difficult to evaluate the success of our business to date and to assess prospects for our future viability.
- We are highly dependent on revenue from the sales of our products, and our inability to successfully execute our growth strategy could negatively affect our results of operations and financial condition.
- Our business is dependent upon the broad adoption and continued use of our products by eyecare professionals and patients.
- We may not be able to secure or maintain adequate levels of third-party coverage and reimbursement for procedures in which our Interventional Glaucoma or Interventional Dry Eye products are used, and third parties may rescind or modify their coverage or delay payments related to these products, which would adversely affect our business, financial condition, and results of operations.
- The market for our products is highly competitive and could grow increasingly competitive as new glaucoma and dry eye technologies are introduced in our industry. Our competitors may have longer operating histories, more established products and distribution networks, lower product prices or greater resources than we do, and may be able to develop or market products that are safer, more effective or gain greater acceptance in the marketplace than our products.
- Adoption of our products depends upon appropriate physician training, practice and patient selection.
- Development of our products for expanded indications depends upon positive clinical data, and applicable regulatory authorities may determine that the safety and efficacy of our products for the intended uses for which we intend to seek clearance, certification or approval are not yet supported by long-term clinical data, which could delay or prevent clearance by the FDA (or other foreign authorities or notified bodies) or limit sales, and our products might prove to be less safe or effective than initially thought.
- We rely on third parties to manufacture and supply all of our products, and a substantial portion of our products and components are manufactured in China. A number of our suppliers are also single-source providers. We are subject to numerous risks relating to our reliance on such third-party suppliers, including the impact of tariffs on products imported from China.
- Uncertainty in current global economic and political conditions could adversely affect our ability to predict product demand and costs and impact our financial results, and makes it more likely that our results will differ materially from expectations.
- We may provide inadequate training, fail to maintain effective sales and marketing capabilities or fail to develop broad brand awareness in a cost-effective manner.
- We have limited experience in training ECPs on, and marketing and selling, our TearCare products, which could adversely affect customer perceptions and adoption of our TearCare products.
The other 41 risks
- Our products are designed to be used in a limited number of procedures, and there is a limited total addressable market for our products. The sizes of the potential and actual markets for our current products have not been established with precision and may be smaller than we estimate, which could adversely impact our results of operations and our growth expectations.
- Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.
- Our long-term growth depends on our ability to continue to capture market share, enhance our products, maintain appropriate product reimbursement, expand our indications and develop and commercialize additional products in a timely manner. If we fail to identify, acquire and develop other products as needed, we may be unable to grow our business.
- Our quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of our business.
- Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and results of operations. Consolidation in the healthcare industry or group purchasing organizations could lead to demands for price concessions, which may affect our ability to sell our products at prices necessary to support our current business strategies.
- We may be unable to manage the anticipated growth of our business, including anticipated growth in our Interventional Dry Eye business.
- Performance issues, service interruptions or price increases by our shipping carriers and distributors could negatively affect our business, financial condition and results of operations and harm our reputation and the relationship between us and the ECPs we work with.
- Our products may become obsolete in the future.
- We may need additional funding to finance our planned operations, and may not be able to raise capital on acceptable terms, if at all, which could force us to delay, reduce or eliminate our product development programs and commercialization efforts.
- We bear the risk of potential warranty claims on our products.
- We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or product improvements or the generation of significant future revenue.
- We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees will negatively affect our business, financial condition and results of operations.
- The use, misuse or off-label use of our products may result in injuries that lead to product liability suits, which could be expensive, divert management’s attention and harm our reputation and business. We may not be able to maintain adequate product liability insurance.
- We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future.
- We may seek to grow our business through acquisitions of or investments in new or complementary businesses, products or technologies, and the failure to manage acquisitions or investments, or the failure to integrate them with our existing business, could have a material adverse effect on us.
- Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or our customer’s patients, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
- Our international business operations expose us to market, legal, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.
- Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
- Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate.
- We could be adversely affected by violations of the FCPA and similar worldwide anti-bribery laws, anti-boycott and anti-money laundering laws and export regulations, and the outcome of any investigation, by government agencies of possible violations by us of these laws and regulations could have a material adverse effect on our business.
- Epidemic diseases, or the perception of their effects, have and may have an adverse effect on our business, financial condition, results of operations, and cash flows.
- Risks Related to Our Intellectual Property
- Our success will depend on our, and our licensors’, ability to obtain, maintain and protect our intellectual property rights.
- Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.
- We are party to, and may in the future become a party to intellectual property litigation or administrative proceedings that can be costly, time-consuming, unsuccessful, and could interfere with our ability to sell and market our products.
- If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed.
- We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors.
- We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
- If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.
- Risks Related to Government Regulation
- Our products, business practices, and operations are subject to extensive government regulation and oversight in the United States and elsewhere.
- We may not receive, or may be delayed in receiving, necessary clearances, certifications or approvals for our future products or modifications to our current products, and failure to timely obtain or retain such clearances, certifications or approvals would adversely affect our ability to grow our business.
- We may incur significant liability if it is determined that we are promoting off-label uses of our products in violation of federal and state regulations in the United States or elsewhere.
- Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market.
- A recall or suspension of our products, or the discovery of serious safety issues with our products, could have a significant negative impact on us.
- If we do not obtain and maintain applicable regulatory registrations, clearances, certifications or approvals for our products, we will be unable to market and sell our products outside of the U.S.
- We are subject to certain federal, state and foreign fraud and abuse laws, health information privacy and security laws and transparency laws that could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.
- If we are found to have violated laws concerning the privacy and security of patient health information or other personal information, we could be subject to civil or criminal penalties, which could increase our liabilities or harm our reputation or business.
- Our employees, consultants, and other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
- Compliance with environmental laws and regulations could be expensive, and the failure to comply with these laws and regulations could subject us to significant liability.
- Risks Related to Our Common Stock
- The price of our common stock may fluctuate substantially or may decline regardless of our operating performance and you could lose all or part of your investment
- If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company.
- Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Legal proceedings
The information set forth under Note 6, Commitments and Contingencies, "Legal Proceedings," to our consolidated financial statements included in this Annual Report on Form 10-K is incorporated herein by reference.
The opening of Item 3, Legal Proceedings.10
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARPaul Badawi, Chief executive officer
- 12
- 13
- 14
- 15
- 16SEC EDGARBrenton Taylor, EVP, Operations
- 17
- 18SEC EDGARJames Rodberg, Officer
- 19SEC EDGARAlison Bauerlein, Officer
- 20
- 21
- 22
- 23SEC EDGARGerhard F. Burbach, Board member
- 24
- 25SEC EDGARTamara Fountain, Board member
- 26SEC EDGARAndrew Offer, Board member
- 27SEC EDGARDonald Zurbay, Board member
- 28SEC EDGARErica J. Rogers, Board member
- 29SEC EDGARMack H. Hicks, Board member
- 30SEC EDGARStaffan Encrantz, Board member
- 31SEC EDGARValeska Schroeder, Board member
- 32SEC EDGARKashif Rashid, General counsel
- 33SEC EDGARJeremy B. Hayden, General counsel
- 34SEC EDGARExecutive or director change
- 35
- 36SEC EDGARShareholder vote
- 37
- 38SEC EDGARRegulation FD disclosure
- 39SEC EDGARRegulation FD disclosure
- 40
- 41SEC EDGAREntered a material agreement
- 42SEC EDGARResults of operations
- 43
- 44
- 45SEC EDGAREntered a material agreement
- 46NasdaqNasdaq calendar
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61